Carlos R. Bachier, MD, discusses how an analysis of 3 clinical trials evaluating the efficacy of lisocabtagene maraleucel demonstrated the feasibility of outpatient administration of chimeric antigen receptor T-cell therapy.
Carlos R. Bachier, MD, of Sarah Cannon Center for Blood Cancer, discusses how an analysis of 3 clinical trials evaluating the efficacy of lisocabtagene maraleucel (liso-cel) demonstrated the feasibility of outpatient administration of chimeric antigen receptor (CAR) T-cell therapy.
Patients with relapsed or refractory large B-cell lymphoma who had undergone at least 2 lines of prior treatment in the TRANSCEND-NHL-001 (NCT02631044) and OUTREACH (NCT03744676) trials, as well as those receiving liso-cel as second-line therapy in the PILOT study (NCT03483103) were followed to determine if administering the CAR T-cell therapy would impact patient safety or treatment efficacy. Centers that administered this therapy to outpatients went through a rigorous vetting and evaluation process to ensure this could be done safely.
The results showed that among those treated in the outpatient setting, liso-cel was safe, there were no unexpected adverse effects, and the response rates were comparable to those seen in patients treated as inpatients. Based on these results, he concluded that closely monitored outpatient administration of liso-cel is feasible.